MX2009009850A - Conjugados de inhibidor de oligomero-proteasa. - Google Patents

Conjugados de inhibidor de oligomero-proteasa.

Info

Publication number
MX2009009850A
MX2009009850A MX2009009850A MX2009009850A MX2009009850A MX 2009009850 A MX2009009850 A MX 2009009850A MX 2009009850 A MX2009009850 A MX 2009009850A MX 2009009850 A MX2009009850 A MX 2009009850A MX 2009009850 A MX2009009850 A MX 2009009850A
Authority
MX
Mexico
Prior art keywords
oligomer
protease inhibitor
inhibitor conjugates
water
protease inhibitors
Prior art date
Application number
MX2009009850A
Other languages
English (en)
Inventor
Jennifer Riggs-Sauthier
Lin Cheng
Tacey X Viegas
Xuyuan Gu
Franco J Duarte
Wen Zhang
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2009009850A publication Critical patent/MX2009009850A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a fármacos de molécula pequeña que son químicamente modificados por unión covalente de un oligómero soluble en agua. Un conjugado de la invención, cuando se administra por cualquiera de un número de rutas de administración, exhibe características que son diferentes del fármaco de molécula pequeña no unido al oligómero soluble en agua.
MX2009009850A 2007-03-12 2008-03-12 Conjugados de inhibidor de oligomero-proteasa. MX2009009850A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90633007P 2007-03-12 2007-03-12
PCT/US2008/003354 WO2008112289A2 (en) 2007-03-12 2008-03-12 Oligomer-protease inhibitor conjugates

Publications (1)

Publication Number Publication Date
MX2009009850A true MX2009009850A (es) 2009-09-24

Family

ID=39577632

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009850A MX2009009850A (es) 2007-03-12 2008-03-12 Conjugados de inhibidor de oligomero-proteasa.

Country Status (10)

Country Link
US (2) US8598364B2 (es)
EP (2) EP2522367B1 (es)
JP (2) JP5448854B2 (es)
KR (1) KR101518079B1 (es)
CN (2) CN101631568B (es)
AU (1) AU2008226823B2 (es)
CA (1) CA2679482C (es)
IL (1) IL200846A (es)
MX (1) MX2009009850A (es)
WO (1) WO2008112289A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3222142A1 (en) 2006-02-28 2017-09-27 Kodiak Sciences Inc. Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US8389759B2 (en) * 2007-03-12 2013-03-05 Nektar Therapeutics Oligomer-anticholinergic agent conjugates
WO2009045539A2 (en) 2007-10-05 2009-04-09 Nektar Therapeutics Al, Corporation Oligomer-corticosteroid conjugates
WO2009114151A1 (en) * 2008-03-12 2009-09-17 Nektar Therapeutics Oligomer-amino acid and olgomer-atazanavir conjugates
US20110195912A1 (en) * 2008-09-17 2011-08-11 Nektar Therapeutics Oligomer-Protease Inhibitor Conjugates
US20110195940A1 (en) 2008-09-17 2011-08-11 Nektar Therapeutics Protease Inhibitors Having Enhanced Features
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
US20120108501A1 (en) * 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN103889434B (zh) * 2011-06-21 2017-02-15 Bvw控股公司 含有乳香酸的医疗装置
CN104230877B (zh) * 2013-06-08 2016-01-27 重庆圣华曦药业股份有限公司 L-（s）-甘油醛缩丙酮的制备方法及其在达芦那韦侧链合成中的应用
DK3041513T3 (da) 2013-09-08 2020-10-26 Kodiak Sciences Inc Zwitterioniske faktor viii-polymerkonjugater
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN104163787A (zh) * 2014-08-08 2014-11-26 山东威智医药工业有限公司 阿扎那韦及其硫酸盐的制备方法
CN107208076A (zh) 2014-10-17 2017-09-26 科达制药 丁酰胆碱酯酶两性离子聚合物缀合物
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US10968318B2 (en) 2017-12-30 2021-04-06 Saint-Gobain Performance Plastics Corporation Heterochain polymer composition
CN109627251B (zh) * 2018-12-29 2021-06-15 常州吉恩药业有限公司 一种高纯度地瑞那韦中间体的工业化生产方法
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
CN115557964A (zh) * 2022-10-18 2023-01-03 启东东岳药业有限公司 一种药物化合物的制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
HU221816B1 (hu) 1991-10-11 2003-01-28 Bristol-Myers Squibb Pharma Company Gyűrűs karbonil vegyületek, és ezeket tartalmazó gyógyászati készítmények
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
SG52731A1 (en) 1991-11-08 1998-09-28 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids
ATE116640T1 (de) 1992-03-13 1995-01-15 Bio Mega Boehringer Ingelheim Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
AU4253193A (en) 1992-05-20 1993-12-13 G.D. Searle & Co. Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DK1302468T3 (da) 1992-12-29 2009-03-02 Abbott Lab Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease
AU7518694A (en) 1993-08-20 1995-03-21 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5732490A (en) 1994-10-27 1998-03-31 Hydary; Mainul H. Perpetual calendar
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
DK0989851T3 (da) 1997-07-29 2003-01-27 Upjohn Co Selvemulgerende formulering indeholdende sure lipofile forbindelser
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
FR2773994B1 (fr) * 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6147095A (en) 1998-11-04 2000-11-14 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
EA011351B1 (ru) * 2003-05-23 2009-02-27 Нектар Терапеутикс Ал, Корпорейшн Полимерные реагенты, способы их получения, а также содержащие их конъюгаты и фармацевтические препараты
CA2549730C (en) 2003-12-16 2012-02-14 Nektar Therapeutics Al, Corporation Chemically modified small molecules
WO2005124563A2 (en) 2004-06-12 2005-12-29 Ceptor Corporation Compounds and kits for treating muscle disorders and methods of use thereof
US6992177B1 (en) 2004-12-10 2006-01-31 Roche Diagnostics Operations, Inc. Saquinavir derivatives useful in immunoassay
WO2006089156A2 (en) 2005-02-16 2006-08-24 Rutgers, The State University Drug-polymer conjugates coupled to a peptidic carrier
EP1857462B9 (en) 2005-02-18 2013-02-13 Nof Corporation Polyoxyalkylene derivative
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US20110195912A1 (en) * 2008-09-17 2011-08-11 Nektar Therapeutics Oligomer-Protease Inhibitor Conjugates
US20120108501A1 (en) * 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors

Also Published As

Publication number Publication date
CN102816111B (zh) 2014-08-06
EP2522367A1 (en) 2012-11-14
WO2008112289A2 (en) 2008-09-18
JP2010522142A (ja) 2010-07-01
CA2679482A1 (en) 2008-09-18
US20110269677A1 (en) 2011-11-03
CN101631568B (zh) 2012-08-22
CN102816111A (zh) 2012-12-12
CA2679482C (en) 2015-04-21
EP2522367B1 (en) 2016-01-20
IL200846A (en) 2014-04-30
JP5448854B2 (ja) 2014-03-19
US20140045770A1 (en) 2014-02-13
JP2014028867A (ja) 2014-02-13
KR20090118965A (ko) 2009-11-18
US9107956B2 (en) 2015-08-18
JP5687752B2 (ja) 2015-03-18
EP2131865A2 (en) 2009-12-16
AU2008226823B2 (en) 2014-03-13
WO2008112289A3 (en) 2008-12-24
AU2008226823A1 (en) 2008-09-18
IL200846A0 (en) 2010-05-17
CN101631568A (zh) 2010-01-20
KR101518079B1 (ko) 2015-05-06
EP2131865B1 (en) 2014-12-17
US8598364B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
MX2009009850A (es) Conjugados de inhibidor de oligomero-proteasa.
MX2009009851A (es) Conjugados de agonistas de oligomeros-opioides.
MY184464A (en) Combined use of cholestanol derivative
MX2010005813A (es) Conjugados oligomero-triciclicos.
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
NZ745318A (en) Pth prodrugs
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
WO2009042064A3 (en) Oligomer-nucleoside phosphate conjugates
AU2015370918A8 (en) Binding protein drug conjugates comprising anthracycline derivatives
WO2009099670A3 (en) Oligomer-cannabinoid conjugates
TN2009000446A1 (en) P70 s6 kinase inhibitors
MX342683B (es) Analogos de ciclopamina.
EA201070786A1 (ru) Бензофуропиримидиноны
CR11136A (es) INHIBICION DE ARNi DE EXPRESION DE ALFA-ENaC
MX2008002492A (es) Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
TNSN08191A1 (en) Kinase inhibitors
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
MY197127A (en) Pyrrolobenzodiazepine conjugates
ZA202001747B (en) Psma-targeting amanitin conjugates
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
WO2009058387A3 (en) Oligomer-nitroimidazole anti-infective conjugates
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MX2009008249A (es) Composicion farmaceutica que comprende derivado de camptotecina.
MX2011007940A (es) Conjugados de oligomero-fenotiazina.
MY165088A (en) Pharmaceutical compositions comprising alisporivir

Legal Events

Date Code Title Description
FG Grant or registration